New Treatment Strategies in the Management of Hormone Refractory Prostate Cancer (HRPC): Only Chemotherapy?

European Urology

Volumn 52, Issue 4, 2007, Pages 945-947

  Sciarra, Alessandro ^a   Salciccia, Stefano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHROMOGRANIN A; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; ESTROGEN; LUTEINIZING HORMONE DERIVATIVE; NAVELBINE; SOMATOSTATIN DERIVATIVE; ZOLEDRONIC ACID;

BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; EDITORIAL; GYNECOMASTIA; HUMAN; MASTALGIA; MONOTHERAPY; NEUROENDOCRINE DISEASE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

ANTINEOPLASTIC AGENTS; DIPHOSPHONATES; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS; TAXOIDS; VINBLASTINE;

EID: 34548275057     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2007.03.029     Document Type: Editorial

References (10)

1. Landstrom M., Damber J.E., and Bergj A. Prostatic tumor regrowth after initially successful castration therapy may be related after to a decreased apoptotic cell death rate. Cancer Res 54 (1994) 4281-4295
2. Yagoda A., and Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 (1993) 1098-1109
3. Sciarra A., Monti S., Gentile V., Mariotti G., Voria G., and Di Silverio F. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 55 (2003) 168-179
4. Sciarra A., Bosman C., Monti S., et al. Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma. J Urol 172 (2004) 1775-1783
5. Koutsilieris M., Mitsiades C., Dimopoulos T., Iannidis A., Ntounis A., and Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical response to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 86 (2001) 5729-5736
6. Di Silverio F., and Sciarra A. Combination therapy of ethinyoestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin A in patients with androgen ablation refractory prostate cancer. J Urol 170 (2003) 1812-1818
7. Tannock I.F., de Wit R., and Berry W. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
8. Petrylak D.P., Tangen C.M., and Hussain M.H. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 351 (2004) 1513-1520
9. Di Lorenzo G., Autorino R., Perdonà S., et al. Docetaxel, vinorelbine and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol 52 (2007) 1020-1027
10. Saad F., Gleason D.M., and Murray R. Long term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882